Gilead’s $11.5B Bet: What Two Companies Saw in One Week
Gilead and UCB deployed $3B+ on similar autoimmune drugs within days. What this pharmaceutical investment convergence signals for institutional investors tracking women’s health.
Healthcare Innovation
The Future of Healthcare Innovation
How aging populations, rising costs, and institutional inertia quietly reshaped medicine into one of the largest sectors of the modern